Extracellular Matrix Survival Signals Transduced by Focal Adhesion Kinase Suppress p53-mediated Apoptosis by Ilić, Duško et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/98/10/547/14 $2.00
The Journal of Cell Biology, Volume 143, Number 2, October 19, 1998 547–560
http://www.jcb.org 547
 
Extracellular Matrix Survival Signals Transduced by Focal
Adhesion Kinase Suppress p53-mediated Apoptosis
 
Du
 
¹
 
ko Ili ,* Eduardo A.C. Almeida,* David D. Schlaepfer,
 
§
 
 Paul Dazin,
 
‡
 
 Shinichi Aizawa,
 
i
 
and Caroline H. Damsky*
 
*Departments of Stomatology and Anatomy, 
 
‡
 
Howard Hughes Medical Institute, University of California San Francisco, San 
Francisco, California 94143-0512; 
 
§
 
The Scripps Research Institute, Department of Immunology, La Jolla, California 92037; and 
 
i
 
Department of Morphogenesis, Institute of Molecular Embryology and Genetics, Kumamoto University School of Medicine, 
Kumamoto 860, Japan
´ c
 
Abstract. 
 
In many malignant cells, both the anchorage 
requirement for survival and the function of the p53 tu-
mor suppressor gene are subverted. These effects are 
consistent with the hypothesis that survival signals from 
extracellular matrix (ECM) suppress a p53-regulated 
cell death pathway. We report that survival signals from 
fibronectin are transduced by the focal adhesion kinase 
(FAK). If FAK or the correct ECM is absent, cells
enter apoptosis through a p53-dependent pathway
 
activated by protein kinase C 
 
l
 
/
 
i
 
 and cytosolic phos-
 
pholipase A
 
2
 
. This pathway is suppressible by domi-
nant-negative p53 and Bcl2 but not CrmA. Upon inacti-
vation of p53, cells survive even if they lack matrix 
signals or FAK. This is the first report that p53 moni-
tors survival signals from ECM/FAK in anchorage-
dependent cells.
Key words: fibronectin • survival • FAK • p53 •
apoptosis
 
C
 
ell
 
 survival depends on multiple factors, including
signals from cell–cell interactions, the extracellu-
 
lar matrix (ECM),
 
1
 
 and soluble survival/growth
factors in serum. When these signals are interrupted, or
when stressful conditions such as DNA damage occur,
normal cells may undergo apoptosis, a physiological form
of programmed cell death (Steller, 1995; Thompson, 1995;
Chinnaiyan and Dixit, 1996, 1997; Levine, 1997). Pro-
grammed cell death contributes to the normal morphoge-
netic programs of most tissues and organs (Jacobson et al.,
1997), and defects in the regulation of apoptosis are
closely correlated with developmental abnormalities, as
well as with the pathophysiology of autoimmune diseases
and cancer (Hunter, 1997).
Signals from the ECM may play a particularly important
role in maintaining normal cytoarchitecture and turnover
in mature tissues because of the anchorage-dependence
for cell growth and survival exhibited by most normal cell
types. During metastatic progression, however, cells lose
this anchorage dependence and also display altered adhe-
sive and migratory properties, allowing them to metasta-
size and to survive and grow in inappropriate environ-
ments. It is therefore important to understand at the
molecular level how signals from ECM suppress cell
death, and what apoptotic pathway is triggered in normal
cells when these signals are lost.
Apoptosis can be triggered by multiple mechanisms.
Specific soluble factors such as Fas ligand or tumor necro-
 
sis factor-
 
a
 
 (TNF-
 
a
 
) bind their receptors and directly acti-
vate a caspase cascade that leads to programmed cell
death (Chinnaiyan and Dixit, 1997). There is strong evi-
dence that the tumor suppressor protein p53 mediates apop-
tosis in response to conditions that generate genomic in-
stability (Ko and Prives, 1996; Levine, 1997). Cells lacking
survival signals from soluble factors transduced by their
receptors and/or ECM survival signals transduced by inte-
grins also undergo apoptosis (Frisch and Ruoslahti, 1997).
Whether there is a role for p53 in stimulating an apoptotic
pathway when survival signals from ECM are absent has
not been established. However, mutations in p53 are com-
 
Du
 
¹
 
ko Ili  and Eduardo A.C. Almeida contributed equally to this work.
Address all correspondence to Caroline H. Damsky, Ph.D, University
of California San Francisco, 513 Parnassus Avenue, HSW-604, San Fran-
cisco, CA 94143-0512. Tel.: (415) 476-8922. Fax: (415) 502-7338. E-mail:
damsky@cgl.ucsf.edu
 
1. 
 
Abbreviations used in this paper
 
: cPLA
 
2
 
, cytosolic phospholipase A
 
2
 
;
DiI-Ac-LDL, DiI-labeled acetylated low-density lipoprotein; E, embry-
onic day; EB, embryoid bodies; ECM, extracellular matrix; ES, embryoid
stem cells; FAK, focal adhesion kinase; FAT, focal adhesion targeting;
FRNK, FAK-related nonkinase; GFP, green fluorescent protein; GSE, ge-
netic suppressor element; HA, hemagglutinin; PECAM-1, platelet–endo-
thelial cell adhesion molecule; PI3K, phosphatidylinositol-3
 
9
 
-kinase; PKC,
protein kinase C; PLC-
 
g
 
, phospholipase C-
 
g
 
; pmT, polyoma middle T;
RSF, rabbit synovial fibroblasts; TNF-
 
a
 
, tumor necrosis factor-
 
a
 
;
TUNEL, terminal deoxynucleotidyl transferase (TdT)-mediated dUTP
nick end labeling.
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mon in many malignant cell types. The fact that such cells
are also no longer anchorage dependent for growth and
survival is consistent with the hypothesis that survival sig-
nals from ECM, transduced by integrins, suppress p53-reg-
ulated apoptosis.
Integrins are receptor 
 
ab
 
 heterodimers with overlap-
ping specificity toward ECM components (Damsky and
Werb, 1992; Hynes, 1992). Integrin-mediated cell–ECM
interactions promote the assembly of cytoskeletal and sig-
naling molecule complexes at sites called focal adhesions.
These complexes include Src-family members, focal adhe-
sion kinase (FAK), phosphatidylinositol-3
 
9
 
-kinase (PI3K),
and phospholipase C (PLC)-
 
g
 
 (Miyamoto et al., 1995
 
a
 
,
 
b
 
;
Plopper et al., 1995). Integrin ligation activates FAK,
which in turn interacts directly with other nonreceptor
protein tyrosine kinases, adaptor molecules, and cytoskel-
etal proteins (Schaller et al., 1994; Schlaepfer et al., 1994;
Hanks and Polte, 1997; Ili  et al., 1997; Schlaepfer and
Hunter, 1998).
Integrin–FAK signaling complexes have been impli-
cated in the regulation of anchorage-dependent cell sur-
vival. Thus, Hungerford et al. (1996) showed that cells be-
come apoptotic if they are microinjected with anti-FAK
antibodies, or with a peptide corresponding to the portion
of the 
 
b
 
1
 
 integrin cytoplasmic domain thought to be re-
quired for 
 
b
 
1
 
–FAK interaction. In another study, Frisch
et al. (1996) showed that constitutively activating FAK by
tethering it to the plasma membrane protected MDCK
cells from apoptosis caused by loss of matrix contact. Fur-
thermore, Xu et al. (1996) reported that attenuation of
FAK expression leads to apoptosis in tumor cells.
The mechanism by which the integrin–FAK signaling
pathway suppresses apoptosis is still largely unknown, as is
the apoptotic pathway triggered when integrin–FAK sig-
nals are interrupted. In this study, we tested the hypothesis
that survival signals from ECM, transduced by integrins
and FAK, suppress a p53-regulated apoptotic pathway.
We used multiple strategies to inactivate FAK and p53 in
endothelial cells and fibroblasts under conditions in which
the cells were anchorage dependent for survival. Our re-
sults document that survival signals from ECM are trans-
mitted by FAK in both cell types, and that in the absence
of FAK function, a p53-regulated apoptotic pathway is ac-
tivated through cytosolic phospholipase A
 
2
 
 (cPLA
 
2
 
) and
the Ca
 
2
 
1
 
 and diacylglycerol-independent 
 
l
 
/
 
i
 
 isoform of
protein kinase C (PKC). This pathway is Bcl2 suppressible
and CrmA resistant and can be repressed by overexpres-
sion of the p53 COOH-terminal domain. Thus, this path-
way is distinct from both the Fas-induced direct death
pathway and other known p53-mediated pathways. This is
the first report of a role for p53 in monitoring survival sig-
nals from ECM and FAK in anchorage-dependent cells.
 
Materials and Methods
 
Mice
 
Previous studies have described the FAK
 
2
 
 (Furuta et al., 1995; Ili  et al.,
1995
 
b
 
) and p53
 
2
 
 mice (Tsukada et al., 1993). Before these studies, both
strains had been backcrossed to obtain mice with defects in both 
 
fak
 
 and
 
p53
 
. Inheritance of mutated 
 
fak
 
 and 
 
p53
 
 alleles was determined by PCR
analysis (Tsukada et al., 1993; Furuta et al., 1995). Mice were bred and
maintained at Kumamoto University Medical School (Kumamoto, Japan)
´ c
´ c
 
and the University of California San Francisco. Their care was in accor-
dance with guidelines of the respective institutions.
 
Cell Lines
 
Rabbit synovial fibroblasts (RSF) were isolated as described previously
(Huhtala et al., 1995). Primary cultures were expanded up to passage 3
and frozen. Cells were used between passages 4 and 8. Wild-type and
FAK-deficient TT2 embryonic stem (ES) cells and FAK-deficient embry-
onic fibroblasts were described previously (Ili
 
 
 
et al., 1995
 
a
 
,
 
b
 
).
Endothelial cells were isolated as follows from E8.0-old 
 
fak
 
1
 
 or 
 
fak
 
2
 
embryos that also carried mutated 
 
p53
 
. Embryonic day 8 (E8.0) embryos
dissected from implantation sites were mechanically disaggregated, plated
on fibronectin-coated dishes (10 
 
m
 
g/ml), and cultured until confluent in
DME with 10% heat-inactivated FCS, sodium pyruvate, nonessential
amino acids, 10
 
2
 
4
 
 M 
 
b
 
-mercaptoethanol, and penicillin/streptomycin.
Cells were detached by enzyme-free PBS-based cell dissociation buffer
(GIBCO BRL; Life Technologies, Grand Island, NY), washed with cold
PBS, and incubated with rotation for 1 h at 4
 
8
 
C with a rat monoclonal
MEC13.3 anti-CD31 (platelet–endothelial cell adhesion molecule [PE-
CAM]-1) antibody (gift of Dr. E. Dejana, Mario Negri Institute, Milan,
Italy). Cells that bound the anti–PECAM-1 were then separated using
anti–rat Ig-coated magnetic beads (Dynal A.S., Oslo, Norway). After five
washes in cold 0.5% BSA/PBS, cells were replated. The purification pro-
cedure was repeated twice more after cells reached confluence.
Endothelial cells with an intact 
 
p53
 
 gene were isolated from embryoid
bodies (EB) derived from wild-type and FAK-deficient TT2 ES cells and
then transformed by polyoma middle T (pmT) retrovirus (Fennie et al.,
1995). To generate EB for endothelial cell isolation, FAK
 
1
 
 and FAK
 
2
 
TT2 ES cells were cultured for 11 d in suspension in serum-containing me-
dium in the absence of leukemia inhibitory factor. The resulting EB were
dispersed with vigorous pipetting in a trypsin/dispase/collagenase solution.
Cells were passed through cell strainers to remove remaining clumps,
washed, and replated. After reaching confluence, endothelial cells were
isolated after incubation with anti–PECAM-1 and IgG-coated magnetic
beads, as described above, and plated. The psi-Cre/psi-Crip retroviral
packaging system transfected with plasmid containing the genome of
pmT–antigen/Neo
 
r
 
 retrovirus was provided by C. Fennie and L. Lasky
(Genentech, San Francisco, CA). Viral titer in supernatants used for
transformation was 
 
z
 
10
 
5
 
 cfu/ml. Infection of the once-selected endothe-
lial cell cultures was performed for 4 h with viral supernatant and poly-
brene as an enhancer (Fennie et al., 1995). Most cells continued to prolif-
erate. Endothelial cells were purified through two more cycles using
MEC13.3 anti-CD31 (PECAM-1) antibody and anti–rat Ig-coated mag-
netic beads.
 
Analysis of Cell Death in EB
 
Wild-type and FAK-deficient TT2 ES cells were cultured in suspension in
the presence of serum-containing medium (DME containing sodium pyru-
vate, nonessential amino acids, 10
 
2
 
4
 
 M 
 
b
 
-mercaptoethanol, penicillin/
streptomycin, and 10% FBS) for 11 d to form EB (Ili  et al., 1996). They
were then cultured for an additional 24 h in the same medium in the pres-
ence or absence of 10% serum as a source of growth/survival factors. EB
were fixed in 3.7% paraformaldehyde for 20 min and then permeabilized
with 0.2% Triton X-100/PBS for 2 min. After washing in PBS, they were
subjected to terminal deoxynucleotidyl transferase (TdT)–mediated
dUTP nick end labeling (TUNEL) with the In situ Cell Death Detection
Kit as recommended by the manufacturer (Boehringer Mannheim Corp.,
Indianapolis, IN). As a control for nonspecific staining, the reaction mix-
ture was used without enzyme. The last washing was done in 10 
 
m
 
g/ml of
Hoechst 33342/PBS to visualize nuclei. Samples were mounted using
Vectashield (Vector Laboratories, Burlingame, CA). Fluorescein label in-
corporated into nucleotide polymers was detected with an epifluorescence
microscope (model Axiophot; Carl Zeiss, Inc., Thornwood, NY) equipped
with proper filters and photographed (Tri-X film; Eastman Kodak Corp.,
Rochester, NY).
 
FACS
 
®
 
-based Apoptosis Assay
 
Endothelial cell lines were cultured for 48 h with serum and for an addi-
tional 24 h either with or without serum. The apoptotic population was de-
termined by a flow cytometric assay (Hamel et al., 1996). Experiments
were repeated three times. Serum-starved and control cells were resus-
pended in 1 ml ice-cold PBS containing 2% FCS, 3% enzyme-free PBS-
based cell dissociation buffer (GIBCO BRL), and 5 
 
m
 
g/ml propidium io-
´ c
´ c 
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dide (Sigma Chemical Co., St. Louis, MO). Cells were kept on ice until
10–15 min before addition of Hoechst 33342. After equilibration to room
temperature, 4 
 
m
 
g/ml Hoechst 33342 was added to the cell suspension. De-
tection of Hoechst 33342 staining was done after 6 min, using a dual-laser
FACStar
 
1
 
 cell sorter (Becton Dickinson, San Jose, CA).
 
Analysis of Cell Death in Adherent Cells
 
Apoptosis in adherent endothelial cell lines and RSF was analyzed using
either the Annexin v-Biotin Apoptosis Detection Kit (Calbiochem, San
Diego, CA) or Hoechst 33342 staining at 10 
 
m
 
g/ml for 10–15 min. The
large nuclei of normal cells stained faintly with Hoechst 33342, whereas
condensed apoptotic nuclei stained brightly. Simultaneous staining and
quantification with both methods produced similar results.
 
Plasmids
 
The sequence of FAK-related nonkinase (FRNK) was created by the in-
troduction of an AflII site between nucleotides 2134–2139 of the mouse
FAK cDNA, using the primers (5
 
9
 
-GCTCAGCTCAGCACAATCT-
TAAGGGAGGAGAAGGTGCAGC-3
 
9
 
 and 5
 
9
 
-GCTGCACCTTCTC-
CTCCCTTAAGATTGTGCTGAGCTGAGC-3
 
9
 
) and following the pro-
tocol outlined in the QuikChange Mutagenesis kit (Stratagene, La Jolla,
CA). The primers (5
 
9
 
-GATACCTAGCATCTAGCGGTACCATGGC-
AGCTGCTTATC-3
 
9
 
 and 5
 
9
 
-GATAAGCAGCTGCCATGGTACCG-
CTAGATGCTAGGTATC-3
 
9
 
) and the QuikChange protocol were used
to create a KpnI site next to the translational start of the mouse FAK
cDNA cloned into pBluescript. All nucleotide changes were confirmed by
DNA sequencing.
To construct green fluorescent protein–focal adhesion targeting (GFP–
FAT) fusion proteins, normal and mutant FAK cDNAs were cut with
XhoI (at 2628–2633 bp of 
 
fak
 
 cDNA) and BamHI (after double hemag-
glutinin [HA] tag) sites. The fragment was inserted between the XhoI and
BamHI sites in the multicloning site of the pEGFP-C1 expression vector
(CLONTECH Laboratories, Palo Alto, CA). For expressing GFP–FRNK
fusion proteins, the pEGFP-C1 vector was also opened with XhoI at the
multicloning site, blunted, and then cut with BamHI. FRNK was cut at the
newly introduced AflII site and with BamHI located after the double HA
tag. The insert was ligated into the multicloning site of pEGFP-C1 expres-
sion vectors in a way that preserved the continuity of the reading frame
between GFP and FRNK. To generate a GFP–FAK expression vector,
FAK cDNA was cut at the new KpnI site in front of the ATG codon and
the BamHI site after the HA tag and inserted into the pEGFP-C1 vector
at corresponding sites.
To disrupt the paxillin binding site 2, we introduced a stop codon be-
fore the critical R1042 residue and generated mutant GFP–FAT
 
D
 
C13.
GFP–FAT
 
D
 
C13 was created by self-ligation of blunted ends after BclI di-
gestion of demethylated GFP–FAT expression vector.
T367, S372, T373, and S374 in GSE p53 were changed to alanines
using the QuikChange Mutagenesis Kit and primers 5
 
9
 
-CTACCCGAA-
GGCCAAGAAGGGCCAGGCTGGGGCCCGCCATAAAAAACCA-
ATG-3
 
9
 
 and 5
 
9
 
-CATTGGTTTTTTATGGCGGGCCCCAGCCTGGC-
CCTTCTTGGCCTTCGGGTAG-3
 
9
 
. All nucleotide changes were con-
firmed by DNA sequencing.
Mouse Bcl2 was cut out from pBluescript II KS (gift from Z. Werb,
University of California San Francisco) and inserted into the multicloning
site of pCDNA3.1/Hygro expression vector (Invitrogen, Carlsbad, CA).
All blunting and ligation reactions were performed with either blunting
or ligation kits (Takara, Japan, imported by PanVera Corporation, Madi-
son, WI). Plasmid DNAs and agarose-embedded fragments were isolated
using appropriate QIAGEN kits (QIAGEN, Valencia, CA).
The expression vectors were gifts: E1B 19K from E. White (Rutgers
University, Piscataway, NJ) (White and Cipriani, 1990); CrmA from V.
Dixit (University of Michigan, Ann Arbor, MI; Genentech) (Tewari et al.,
1995); p53-175, p53-273, and GSE p53 mutants from T. Tlsty and V. Os-
sovskaya (University of California San Francisco); normal and mutated
PKCs from J. Moscat (Universidad Autonoma, Canto Blanco, Madrid,
Spain) and S. Ohno (Yokohama City University School of Medicine,
Yokohama City, Japan); myristylated HA-tagged AKT from Chiron
Corp. (Emeryville, CA); and cPLA
 
2
 
 from A. Stewart and C. Leslie (Uni-
versity of Colorado, Denver, CO).
 
Matrix Survival Assays
 
Tissue culture plastic wells were coated for 12 h at 4
 
8
 
C with 25 
 
m
 
g/ml of fi-
bronectin, laminin-1, vitronectin, or collagen I (GIBCO BRL). After coat-
 
ing, and just before plating cells, the coated wells were washed with PBS.
Cells for survival assays (RSF and FAK
 
1
 
p53
 
1 
 
endothelial cells) were
grown to subconfluency and detached from plastic culture dishes with en-
zyme-free PBS-based cell dissociation buffer (GIBCO BRL). After wash-
ing with PBS, cells were plated on matrix-coated wells at about 75% con-
fluency in serum-free DME with glutamine and nonessential amino acids.
After 16 or 24 h of culture (RSF and endothelial cells, respectively), apop-
totic cells were quantified as described above.
 
DNA Transfections and Inhibitor Studies
 
Primary fibroblast cultures were transfected using the Lipofectamine Plus
kit (GIBCO BRL) or SuperFect Transfection Reagent (QIAGEN) ac-
cording to the manufacturers’ instructions. We used 0.5 
 
m
 
g (molar quan-
tity) of DNA per cm
 
2
 
 of 75% confluent cells plated for 24 h on fibronectin.
If different DNAs were cotransfected, equimolar amounts of DNA were
used. The cells were incubated with the transfection mixture for 5 h (Lipo-
fectamine method) or 2 h (SuperFect method). Then the transfection mix-
ture was removed and replaced with serum/antibiotic-free DME supple-
mented with glutamine, nonessential amino acids, and pyruvate. After 12 h
of culture, apoptotic cells were quantified as described above.
All inhibitors used in this study were purchased from Calbiochem (San
Diego, CA) and used according to the manufacturer’s recommendation in
concentrations outlined in figures and figure legends.
 
Results
 
Withdrawal of Serum Induces Apoptosis in
FAK
 
2
 
 EB and Endothelial Cells Despite the Presence 
of an Endogenous ECM
 
Survival signals from ECM in cells that are anchorage de-
pendent for survival can be assessed if they are cultured in
the absence of serum but provided with a suitable ECM.
In a direct test of the role of FAK in communicating sur-
vival signals from ECM, we first compared the ability of
EB, derived from wild-type or FAK-deficient ES cells, to
survive after withdrawal of serum (Fig. 1 
 
A
 
). Wild-type
and FAK
 
2
 
 ES cells were grown in suspension for 11 d in
the presence of serum, during which time cells formed
compacted EB surrounded by endoderm. They were then
grown for an additional 24 h in either the presence or ab-
sence of serum. Then the EB were fixed and stained with
the TUNEL in situ cell death detection kit, which recog-
nizes single- and double-stranded DNA breaks occurring
at early stages of apoptosis. Very few cells in either the
FAK
 
1
 
 or FAK
 
2
 
 EB that had been cultured with serum
for the entire 12 d period displayed the intense staining
characteristic of cells undergoing apoptosis (Fig. 1 
 
A
 
, (
 
1
 
)
 
SERUM
 
). However, a large number of cells in the FAK
 
2
 
EB that had been grown for the final 24 h in the absence of
serum displayed strong TUNEL staining (Fig. 1 
 
A
 
, 
 
FAK
 
2
 
,
(
 
2
 
)
 
 SERUM
 
), whereas the number of TUNEL-positive
cells in the FAK
 
1
 
 EB cultured in the absence of serum
(Fig. 1 
 
A
 
, 
 
FAK
 
1
 
, (
 
2
 
) SERUM) was comparable to that in
the EB cultured in the presence of serum for the entire 12 d
of the experiment. These data suggest that FAK is re-
quired for transduction of survival signals in these cultures
when serum is withdrawn.
To study in greater detail the role of FAK in promoting
survival in a specific cell type, we isolated endothelial cell
lines from disaggregated FAK1 or FAK2 EB, or from
E8.0 FAK1 or FAK2 embryos, using magnetic beads
coated with a rat monoclonal antibody (MEC13.3) against
PECAM-1 (CD31). The isolated endothelial cells were ei-
ther immortal as a consequence of being derived fromThe Journal of Cell Biology, Volume 143, 1998 550
FAK1 or FAK2 E8.0 embryos that also carried mutated
p53 or were transformed by introduction of pmT into
FAK1 or FAK2 endothelial cells isolated from EB. The
two latter lines were wild-type for p53. All four lines dis-
played an endothelial phenotype by the following criteria:
(a) uptake of DiI-labeled acetylated low-density lipopro-
tein (DiI-Ac-LDL; Wang et al., 1992); (b) binding of la-
beled Griffonia (Bandeiraea) simplicifolia lectin I–isolec-
tin B4 (Laitinen, 1987); and (c) expression of PECAM-1 as
examined by FACS® using MEC13.3 anti-CD31 antibody
directly conjugated with FITC (data not shown).
The four endothelial lines were cultured for 48 h in the
presence of serum, during which time they elaborated an
endogenous fibronectin-containing fibrillar matrix (data
not shown). The lines were then cultured in either the
presence or absence of serum for an additional 24 h to as-
sess the cells’ ability to survive with their endogenous
ECM as a source of survival signals. The level of apoptosis
in cells harvested from each culture was examined with
flow cytometry, using an assay based on the more rapid
uptake of Hoechst 33342 dye by apoptotic versus normal
nuclei (Hamel et al., 1996). All lines grown continuously in
Figure 1. FAK suppresses
a p53-regulated apoptosis
pathway in embryoid bodies
and endothelial cells. (A)
Withdrawal of serum induces
apoptosis in FAK2 EB gen-
erated from wild-type and
FAK2 TT2 ES cells (Ili  et al.,
1995a). Cells were cultured
for 11 d without leukemia in-
hibitory factor and in the pres-
ence of serum to initiate dif-
ferentiation. They were then
cultured for an additional 24 h
either with (1), or without
(2) serum. The presence of
apoptotic cells was assessed by
TUNEL staining, and nuclei
were visualized with Hoechst
as described in the Materials
and Methods. (B) p53 defi-
ciency permits survival, de-
spite the absence of FAK, in
anchorage-dependent, serum-
deprived endothelial cells. En-
dothelial  cells were isolated
from FAK1 or FAK2 EB or
embryos and immortalized
by pmT or incorporation of
mutated p53, as described in
the Materials and Methods.
Apoptosis was assessed by
a flow cytometric assay: PI,
propidium iodide; Hoechst,
Hoechst 33342. In each plot,
the events represented in red
(upper gated area) correspond
to the PI/Hoechst ratios char-
acteristic of an apoptotic pop-
ulation, whereas the events
represented in green (lower
gated area) correspond to
nonapoptotic cells (Hamel et
al., 1996). Endothelial cell
lines were cultured for 48 h
in the presence of serum and
for an additional 24 h in the
presence (1) or absence (2)
of serum. All endothelial
lines cultured in the presence
´ c
of serum, as well as both p53-deficient cell lines cultured without serum, displayed low levels of apoptosis. Of the two endothelial cell
lines immortalized by pmT, and therefore wild-type for p53, the FAK1 line exhibited a slightly higher level of apoptosis upon serum re-
moval (6.3 vs. 2.1%). However, the FAK2 line showed a much greater (7.8-fold) increase in apoptosis upon serum withdrawal (24.1 vs.
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the presence of serum showed a low level of apoptosis in
this assay (4.3, 1.1, 2.1, and 3.1%: Fig. 1 B, (1) SERUM).
When serum was withdrawn, both p53-deficient endothe-
lial lines continued to display a low level of apoptosis (3.7
and 1.5%: Fig. 1 B, (–) SERUM). Cells that were wild type
for both p53 and fak had nearly as low a level of apoptosis
(6.3%) after serum withdrawal as before (2.1%). How-
ever, the cells that were wild-type for p53, but deficient in
fak, showed a 7.8-fold increase in apoptosis (24.1%) after
serum withdrawal when compared with these same cells
cultured continuously in the presence of serum (3.1%).
Furthermore, the serum-deprived FAK2 cells with intact
p53 displayed almost a fourfold increase in apoptosis when
compared with serum-deprived cells that were wild type
for both genes (Fig. 1 B, (–) SERUM). Extending the time
in the absence of serum to 72 h did not increase the pro-
portion of apoptotic cells in the FAK1 cultures (data not
shown). These observations suggest strongly that, in the
absence of serum factors, p53 triggers increased pro-
grammed cell death in endothelial cells that can be sup-
pressed by survival signals from ECM transduced by FAK.
Specific Matrices Signal Cell Survival in the Absence of 
Serum in Endothelial Cells and Fibroblasts
The experiments described above suggested that a com-
plex endogenous ECM, generated in the presence of se-
rum, could support survival of FAK1 EB and pmT-immor-
talized FAK1p531 endothelial cells after serum withdrawal.
To determine more precisely which matrix components
are critical for supporting survival of the FAK1p531 en-
dothelial cells, we plated these cells on defined ECM
ligands in the absence of serum. We also tested the ability
of ECM ligands to support survival of primary RSF, so as
to determine the cell type specificity of the effects of these
ligands on survival in the absence of serum. In the case of
the endothelial cells, fibronectin and laminin-1 were the
most effective in promoting survival, with vitronectin also
showing substantial survival-promoting activity. Collagen
type I was significantly less effective than the other ECM
ligands (Fig. 2 A). In the case of RSF, fibronectin was
markedly superior to the other three ligands in promoting
survival: the apoptotic index of RSF plated on the latter
matrices was no better than that observed for tissue cul-
ture plastic (Fig. 2 B). Fibronectin was used for subse-
quent experiments since it supported survival of both the
endothelial cells and fibroblasts.
Interference with FAK Function Triggers Apoptosis of 
Primary Fibroblasts in Serum-free Medium
To test the roles of FAK and p53 in regulating survival sig-
nals from fibronectin in RSF, we sequentially inactivated
the functions of endogenous FAK and p53 in these cells.
In the case of FAK, we used two COOH-terminal con-
structs: FRNK and the FAT domain (Fig. 3 A). FRNK is a
naturally occurring alternative transcript to FAK that is
expressed in some cell types and constitutes the sequence
of FAK COOH-terminal to the kinase domain (Richard-
son and Parsons, 1996). FAT is a region within FAK and
FRNK that contains the sequences necessary for targeting
FAK to focal adhesion sites (Hildebrand et al., 1993).
FRNK and FAT can interfere with FAK localization and
signaling (Gilmore and Romer, 1996; Richardson and Par-
sons, 1996). To determine the importance of focal adhe-
sion localization for the activity of FAT, we also tested a
FAT construct in which the COOH-terminal 13 amino ac-
ids were deleted so as to abrogate its ability to target focal
adhesion sites (FATDC13). To follow the expression and
localization of these constructs as well as full-length FAK
in living cells, the cDNA encoding a GFP was fused in-
frame to the NH2 terminus of all of these cDNAs (Fig. 3 A
and Materials and Methods).
When living cultures were examined 8 h after transfec-
tion of these constructs, GFP–FAK, GFP–FRNK, and
GFP–FAT were detected in focal adhesion sites, as well as
diffusely, in successfully transfected cells. In contrast,
GFP–FATDC13 was not detected at focal adhesion sites
(Fig. 3 B). Subsequent fixation and staining of the GFP–
FRNK– and GFP–FAT–transfected cells with an anti-
Figure 2. Specific matrices signal cell survival in the absence of
serum in both endothelial cells and fibroblasts. Tissue culture
plastic wells were either coated with fibronectin (FN), vitronectin
(VN), laminin-1 (LA), or type-I collagen (CO), or not coated
(NC), as described in the Materials and Methods. Cells were
plated for 16 h (primary rabbit synovial fibroblasts: RSF) or 24 h
(EpmTp531FAK1 endothelial cells) on these matrices in the ab-
sence of serum. SE, serum control. Apoptotic cells in the culture
were quantified as described in Materials and Methods. Each
sample of at least 100 cells was obtained in triplicate in each ex-
periment. Experiments were repeated at least three times. Error
bars show SD. (A) FAK1p531 endothelial cells. (B) RSF.The Journal of Cell Biology, Volume 143, 1998 552
Figure 3. GFP–FAT acts as a
dominant negative for FAK.
(A) RSF were transfected
with cDNA encoding a fu-
sion protein containing GFP
and FAK, FRNK, FAT, or
FATD13C (FAT with dele-
tion of 13 COOH-terminal
amino acids). (B) At 8 h, all
fusion proteins except GFP–
FATD13C were detected both
in focal contacts and dif-
fusely in the cytoplasm. (C)
Quantification of the apop-
totic index at 16 h (percent-
age of transfected [green]
cells containing condensed,
fragmenting nuclei, as de-
tected by Hoechst 33342)
for GFP, GFP–FAK, GFP–
FAT, GFP–FRNK, and GFP–
FATD13C transfectants. In
contrast to the high apop-
totic index (75%) after GFP–
FAT transfection, transfec-
tions with GFP alone or with
GFP fused to intact FAK
caused no apoptosis above
levels observed in cells plated
on fibronectin in the ab-
sence of serum (z20%).
GFP–FATD13C, which was
not detected in focal adhe-
sions, was also unable to in-
duce apoptosis to the same
degree as GFP–FAT. (D)
Apoptosis assessed by an-
nexin binding and Hoechst
33342 staining. Most RSF ex-
pressing GFP–FAT, but not
GFP alone or GFP-FAK, are
rounded, and their Hoechst
33342-stained nuclei are bright
and condensed by 16 h after
transfection (arrows). These
same cells also show annexin-
positive staining (red) in the
plasma membrane, indicating they are apoptotic (staining described in Materials and Methods). Untransfected and GFP–FAK–trans-
fected cells are spread (Phase) and have normal nuclei (Hoechst).Ili  et al. FAK, p53, and Survival 553 ´ c
FAK antibody that recognizes the NH2-terminal region of
FAK (and therefore not FAT or FRNK) showed that en-
dogenous FAK was partially or completely displaced from
focal adhesion sites at this time (data not shown).
Apoptosis was assessed in these cultures 16 h after
transfection by adding Hoechst 33342, which reveals
nuclear morphology. The percentage of successfully trans-
fected cells (positive for GFP) that also contained con-
densed/fragmented nuclei was determined as the apop-
totic index for each culture (Fig. 3 C). By 16 h after
transfection, most cells expressing GFP–FAT were scored
as apoptotic (75%). In contrast, GFP–FATDC13 triggered
a much lower level of apoptosis (38%), indicating the sig-
nificance of localization to focal adhesion sites for the
proapoptotic effect of GFP–FAT. The apoptotic indices
for cells transfected with GFP alone or GFP–FAK were
similar to the low level found for untransfected fibroblasts
cultured on fibronectin in the absence of serum (z25%).
Interestingly, cultures transfected with GFP–FRNK had
significantly lower apoptotic indices than cells transfected
with GFP–FAT (31 vs. 75%), even though both could tar-
get focal adhesion sites.
Apoptosis was also assessed in cultures transfected with
GFP alone, GFP–FAK, or GFP–FAT by assessing the
ability of unfixed cells to bind biotinylated annexin (an-
nexin v-biotin). Annexin v-biotin binds to phosphatidyl
serine, which is normally present in the inner leaflet of the
plasma membrane but is translocated to the outer leaflet
in cells undergoing apoptosis, thereby becoming accessible
to the labeled annexin (Martin et al., 1995). The annexin,
Hoechst, and phase microscope images of these cultures
are presented in Fig. 3 D. Most GFP–FAT–expressing
cells showed evidence of karyorhexis and the presence of
brightly stained pyknotic chromatin characteristic of cells
undergoing programmed cell death. In contrast, most un-
transfected cells in the same culture, as well as cells trans-
fected with GFP alone or with full-length FAK fused to
GFP (GFP–FAK), had large, lightly stained nuclei, which
are characteristic of viable cells. The extent of abnormal
nuclear morphology revealed by Hoechst staining corre-
lated highly with annexin binding, thereby confirming by a
different method the apoptotic phenotype of GFP–FAT,
as compared with GFP–FAK– and GFP-transfected cells.
FRNK has been shown to act as a dominant-negative
regulator of FAK for at least some of its functions, includ-
ing cell spreading (Richardson and Parsons, 1996). In our
system, however, z70% of the cells expressing GFP–
FRNK survived, whereas 75% of cells expressing GFP–
FAT died (Fig. 3 C) GFP–FRNK was functional in RSF,
as determined by its ability to delay spreading of
trypsinized and replated GFP–FRNK–expressing RSF
(Fig. 4 A) with a time course similar to that reported by
Richardson and Parsons (1996). Furthermore, GFP–
FRNK and GFP–FAT were expressed at similar levels in
transfected cells, as determined by immunoblotting an
equal number of FACS®-sorted GFP–FRNK– and GFP–
FAT–expressing cells with anti-GFP (Fig. 4 B). These re-
sults are consistent with the proposal that FRNK is a nega-
tive regulator of some (i.e., spreading), but not all (i.e.,
anchorage-dependent survival) functions of FAK. Inter-
estingly, trypsinized and replated GFP–FAT–expressing
cells were virtually unable to spread in spite of their initial
attachment (Fig. 4 A). The time course of GFP–FAT ac-
tion in adherent RSF that were transfected with GFP–
FAT and left undisturbed demonstrates that accumula-
tion of GFP–FAT in focal contacts leads to cell rounding,
detachment, and, ultimately, death (Fig. 3, B and D).
Together, the data in Figs. 3 and 4 support the idea that
Figure 4. Assessment of GFP–FRNK and GFP–FAT function. (A) Cells expressing GFP–FRNK show delayed spreading. RSF trans-
fected with GFP, GFP–FRNK, or GFP–FAT for 10 h were trypsinized and replated on fibronectin-coated coverslips. 60 min after re-
plating, GFP-transfected cells were completely spread, whereas GFP–FRNK and GFP–FAT transfectants were still rounded. By 2 h,
GFP–FRNK–transfected cells had spread, showing focal contact localization of the fusion protein (arrowheads). However, a majority
of GFP–FAT–transfected cells remained round, although still attached. (B) Transfected cells express similar amounts of GFP–FRNK
and GFP–FAT. Cells expressing GFP–FRNK or GFP–FAT were sorted by FACS® 10 h after transfection. An equal number of sorted
cells (5 3 103) of each type were lysed in RIPA buffer, separated on 10% SDS-PAGE, transferred to nitrocellulose, and probed with
anti-GFP antibody (Zymed Laboratories, So. San Francisco, CA). Bands were visualized by ECL-Plus detection system (Amersham
Corp., Arlington Heights, IL).The Journal of Cell Biology, Volume 143, 1998 554
FAT acts as a dominant negative for FAK, interfering with
its ability to detect and/or transmit survival signals from fi-
bronectin. In the absence of these FAK-transduced sig-
nals, apoptosis was triggered, as was observed for the se-
rum-deprived, p531FAK2 endothelial cells (Fig. 1 B).
Activation of the PI3K/AKT Pathway Does Not Rescue 
Cells from Death Caused by GFP–FAT
Activated FAK has been shown to bind the p85 regulatory
component of PI3K. Furthermore, formation of FAK/p85
complexes and elevated levels of phosphatidylinositol 3,4-
diphosphate and 3,4,5-triphosphate (products of PI3K
activity), followed by activation of AKT, occur after at-
tachment of cells to ECM (Khwaja et al., 1997). If an an-
chorage-inducible PI3K/AKT pathway is downstream of
FAK in the survival pathway in cells that are cultured un-
der anchorage-dependent conditions, then expression of
constitutively active myristylated AKT (Kohn et al., 1998)
should rescue cells transfected with GFP–FAT from pro-
grammed cell death. We therefore transfected GFP–FAT
along with HA-tagged myristylated AKT into RSF cul-
tured on fibronectin in serum-free medium. The AKT con-
struct was correctly localized, as determined by anti-HA
tag antibody staining, and was active in rescuing cells from
apoptosis induced by overexpression of the FAK-related
kinase, PYK2, under the serum-replete culture conditions
used by Xiong and Parsons (1997). However, it did not
rescue cells dependent on ECM survival signals from
apoptosis induced by GFP–FAT (Fig. 5). Furthermore,
addition of the stable PI3K inhibitor LY294002 was un-
able to induce apoptosis of either untransfected cells or
cells transfected with GFP alone and cultured in serum-
free medium on fibronectin (Fig. 5). These data suggest
that the ECM survival pathway downstream of FAK is dis-
tinct from the PI3K/AKT survival pathway that is sup-
pressed when PYK2 is overexpressed (Xiong and Parsons,
1997), illustrating the existence of multiple survival path-
ways in cells.
Apoptosis Induced by FAK Inactivation in
Anchorage-dependent, Serum-deprived Fibroblasts Is 
Initiated through a p53-regulated Pathway
Turning to the apoptotic pathway triggered by FAK inac-
tivation in anchorage-dependent serum-deprived fibro-
blasts, we used several approaches to test whether p53 was
involved, as we had demonstrated for endothelial cells
(Fig. 1 B). In all cases, we determined whether interfering
with p53 function or p53 signaling pathways could rescue
GFP–FAT–induced apoptosis. The E1B 19K adenoviral
protein inactivates the p53 apoptotic pathway triggered by
genomic instability (White and Cipriani, 1990; Debbas and
White, 1993; Ko and Prives, 1996; Levine, 1997). Cotrans-
fection of the E1B 19K expression vector along with GFP–
FAT into serum-deprived RSF plated on fibronectin re-
sulted in a low (background) level of apoptosis (19%; Fig.
6 A), despite the fact that FAK function was inactivated by
GFP–FAT. In another approach to interfering with the
pathway by which p53 mediates apoptosis (Ko and Prives,
1996; Levine, 1997), Bcl2 was overexpressed in GFP–
FAT–transfected RSF. Coexpression of Bcl2 along with
GFP–FAT also suppressed apoptosis extensively (35 vs.
82%; Fig. 6 A).
To demonstrate the involvement of p53 more directly,
we cotransfected (along with GFP–FAT) a genetic sup-
pressor element (GSE) that corresponds to the COOH-
terminal domain of p53 (C-term p53, amino acids 312–391
of the rat p53; Ossovskaya et al., 1996). Expression of this
construct along with GFP–FAT reduced the apoptotic in-
dex significantly (85 vs. 38%: P , 0.01). However, when
serines and threonines that are likely phosphorylation
sites for PKC (T367, S372, T373, and S374; Milne et al.,
1996) were replaced by alanines (mut C-term p53), the
construct was no longer able to rescue GFP–FAT–induced
apoptosis (Fig. 6 A). This experiment suggests that the
C-term p53 GSE functions by a dominant-negative mecha-
nism that interferes with phosphorylation of endogenous
p53. Attempts to interfere with p53 function by missense
mutations of the DNA binding region at R273 and R175
did not rescue cells from GFP–FAT–induced apoptosis
(data not shown). Together, these data point to p53 as a
monitor of survival signals transduced by FAK in fibro-
blasts as well as endothelial cells. The fact that mutating
putative PKC phosphorylation sites in the C-term p53
fragment abrogates its ability to interfere with endogenous
p53 regulation of apoptosis suggests that this p53-regu-
lated apoptotic pathway is activated by one or more iso-
forms of PKC when the appropriate ECM or FAK is ab-
sent.
Figure 5. The PI3K/AKT pathway cannot rescue the apoptotic
response of RSF to GFP–FAT. In RSF cultured on fibronectin
without serum, blockade of PI3K activity by LY294002 did not
trigger apoptosis, nor did cotransfection of constitutively acti-
vated AKT (myr AKT) along with GFP–FAT block apoptosis.
This suggests that PI3K/AKT are not downstream mediators of
the FAK survival pathway in serum-deprived, anchorage-depen-
dent cells.Ili  et al. FAK, p53, and Survival 555 ´ c
Atypical PKC l/i and cPLA2 Are Involved in the 
Pathway That Activates p53-mediated Apoptosis after 
Interruption of Survival Signals from ECM
Several lines of evidence suggest that a large group of
serine/threonine kinases termed PKC are involved in reg-
ulating attachment and spreading of cells on ECM (Chun
and Jacobson, 1993) and in regulating both cell survival
and cell death (Livneh and Fishman, 1997). The many
isoforms of PKC have been divided into three groups:
classical (a, b, and g), which are Ca21- and diacylglyc-
erol-dependent forms; novel (d, e, h, and u), which are
Ca11-independent but diacylglycerol-dependent forms;
and atypical (z and l/i), which are Ca21- and diacylglyc-
erol-independent forms (Livneh and Fishman, 1997). We
used several approaches to analyze whether PKC isoforms
are engaged either in transduction of survival signals from
ECM or in the induction of apoptosis when such signals
are withdrawn. In a pharmacological approach, we deter-
mined that bisindolylmaleimide I and chelerythrine chlo-
ride, inhibitors that affect all PKC isoforms, were able to
reduce the apoptotic index significantly in cultures of
GFP–FAT–transfected RSF (85 vs. 25–30%) (Fig. 6 B).
However, calphostin C, which specifically blocks diacyl-
glycerol-dependent (classical and novel) PKC isoforms,
did not suppress GFP–FAT–induced apoptosis. To evalu-
ate these results in terms of the RSF system, we detected
expression of only the l/i and e PKC isoforms in these
cells (Fig. 6 C). This suggests that for RSF, the atypical
PKC isoforms l/i are the likely candidates for participat-
ing in the apoptotic pathway activated when FAK function
is suppressed. Indeed, cotransfection of either GFP or
GFP–FAT with dominant-negative constructs of the PKC
isoforms detected in RSF confirmed this idea. Thus, domi-
nant-negative l/i was able to rescue cells from GFP–FAT–
mediated death, whereas dominant-negative PKC e did
not (Fig. 6 D). Neither construct affected survival when
cotransfected with GFP alone.
PKC activation by lipid mediators is dependent on re-
lease of arachidonic acid from phospholipids. Addition of
100 mM arachidonic acid for 6 h to RSF that had attached
and spread on fibronectin in serum-free medium triggered
apoptosis in untransfected cells and cells transfected with
GFP alone and increased the level of apoptosis triggered
by transfection of GFP–FAT (Fig. 6 E). Arachidonic acid
is either hydrolytically removed from phospholipids by
PLA2 or produced from diacylglycerol, which is released
by the action of PLC. Activation of PKC by arachidonic
acid can be independent of, or synergistic with, diacylglyc-
erol. Since the l/i PKC isoforms implicated above are
atypical (Ca21 and diacylglycerol independent), we would
predict that PLA2 rather than PLC would be involved in
PKC l/i activation in this pathway. Studies with pharma-
cological inhibitors showed that U-73122, a specific PLC
inhibitor, was unable to rescue cells from apoptosis trig-
gered by GFP–FAT transfection of RSF cultured on fi-
bronectin in serum-free medium (Fig. 6 E). However,
arachidonyltrifluoremethyl ketone (AACOCF3), a cPLA2
inhibitor, significantly improved the survival rate of GFP–
FAT–transfected cells (85 vs. 40%: P , 0.01) (Fig. 6 E).
These studies implicate cPLA2 and PKC l/i as partici-
pants in activating the p53-regulated apoptotic pathway
when ECM survival signals are absent. To determine
whether they are part of the same pathway, we tested
whether the pan-PKC inhibitor bisindolylmaleimide I
could inhibit the high level of apoptosis triggered by addi-
tion of arachidonic acid; our results showed that it could
(Fig. 6 E). Thus, our data are consistent with the idea that
ECM survival signals transduced by FAK in primary fibro-
blasts suppress a p53-regulated apoptotic pathway acti-
vated by cPLA2 and PKC l/i.
The p53-regulated Apoptotic Pathway Triggered
by Loss of ECM/FAK Signals Is Not Dependent on 
Large Prodomain Caspases
The activation of a caspase/interleukin 1b-converting en-
zyme protease cascade has been implicated in both the ini-
tiation as well as the execution phases of several apoptotic
pathways. The activity of the large prodomain caspases
(e.g., caspases 2 and 8) implicated in the initiation of apop-
tosis by death ligands such as Fas ligand and TNF-a is in-
hibitable by CrmA, a cowpox virus–derived protein (Te-
wari et al., 1995; Villa et al., 1997; Wen et al., 1997). If
large prodomain caspases are critical for driving apoptosis
triggered by the absence of functional FAK in anchorage-
dependent, serum-starved RSF, CrmA should block apop-
tosis in GFP–FAT–expressing cells. However, there was
no significant difference in the extent of apoptosis in cul-
tures cotransfected with GFP–FAT plus CrmA versus
those transfected with GFP–FAT alone (Fig. 6 F). Thus,
in anchorage-dependent, serum-deprived RSF, suppres-
sion of FAK function triggers apoptosis through a CrmA-
insensitive pathway.
Small prodomain caspases, such as caspase-3, -6, -7, and
-9, are thought to be final executors in cell death regard-
less of the initial signal. Therefore, an inhibitor of these
caspases, such as Z-VAD-FMK, should prevent the final
stages, although not the initial stages, of programmed cell
death triggered by GFP–FAT inactivation of FAK func-
tion in anchorage-dependent fibroblasts. Indeed, when
cultured on fibronectin in serum-free medium, but in the
presence of Z-VAD-FMK, most GFP–FAT–transfected
fibroblasts were rounded. However, nuclei were not con-
densed and fragmented, and therefore these cells were still
scored as viable. In contrast, 70–80% of the GFP–FAT–
transfected RSF cultured under the same conditions in the
absence of Z-VAD-FMK displayed the full apoptotic ef-
fect, including fragmented nuclei (Fig. 6 F).
Discussion
Adhesion of many anchorage-dependent cells to ECM is
essential for their survival in the absence of trophic factors
from serum. If contact with appropriate ECM is denied to
such cells, they rapidly undergo apoptosis. After ascertain-
ing that fibronectin was a highly effective survival-promot-
ing ECM ligand for both endothelial cells and primary fi-
broblasts, we demonstrated four important points in this
study related to the transduction of survival signals from
ECM in anchorage-dependent cells (Fig. 7): (a) Survival
signals from fibronectin are transduced through FAK in
both fibroblasts and endothelial cells. (b) The absence of
either FAK or an appropriate ECM triggers a p53-regu-The Journal of Cell Biology, Volume 143, 1998 556
Figure 6. Characterization of the apoptotic pathway triggered in the absence of ECM sur-
vival signals in serum-deprived RSF: pharmacological and dominant-negative strategies re-
veal an apoptotic pathway that is regulated by p53, activated by cPLA2 and PKC l/i, and re-
sistant to CrmA. (A) Blocking the function of p53 permits survival of primary RSF despite
suppression of FAK function by GFP–FAT. GFP–FAT was cotransfected into fibroblasts
plated on fibronectin, with or without either E1B 19K, Bcl2, or a GSE corresponding to the
COOH-terminal domain of p53 (C-term p53), which inactivates p53 function (see Materials
and Methods). The apoptotic index was high in GFP–FAT–transfected cells, but greatly re-
duced in cells cotransfected with GFP–FAT and one of the following: E1B 19K, Bcl2, or
C-term p53. However, cotransfection of C-term p53, which contained mutated putative PKC
phosphorylation sites (mut C-term p53), with GFP–FAT did not rescue cells from apoptosis.
(B–D) Apoptosis triggered by inactivation of FAK function in serum-deprived anchorage-
dependent RSF requires PKC l/i. (B) Inhibitors that block function of all isoforms of PKC
(bisindolylmaleimide I and chelerythrine chloride) suppressed GFP–FAT–induced apopto-Ili  et al. FAK, p53, and Survival 557 ´ c
sis, whereas calphostin C, which blocks only the PMA-sensitive isoforms (and therefore not PKC l/i), did not. (C) RSF express three
isotypes of PKC. To detect PKC isotypes, cells were lysed using RIPA buffer in the presence of proteinase inhibitors. PKCs were immu-
noprecipitated and detected with anti-PKC a, b, g, d, e, z, o, i, l, and m antibodies (Transduction Laboratories, Lexington, KY) after
separation in 10% SDS–polyacrylamide gels. Only PKC e, l, and i were detected. 1 control, PKC isoform standard; 2 control, precipi-
tation of RSF lysate with nonimmune IgG; anti-PKC, precipitation with antibodies specific for the PKC isoforms. (D). Coexpression of
dominant-negative (DN) PKC l/i, but not DN PKC e, blocked GFP–FAT–triggered apoptosis. Cotransfection of the wild-type PKC iso-
forms with GFP–FAT did not rescue cells from apoptosis. Transfection of wild-type isoforms into GFP-transfected cells did not pro-
mote apoptosis. (E) Apoptosis triggered by inactivation of FAK function in serum-deprived anchorage-dependent RSF requires cPLA2.
Arachidonic acid induced apoptosis in nontransfected or GFP-transfected RSF. Phospholipases catalyze the release of arachidonic acid
from phospholipids. AACOCF3, an inhibitor of cPLA2, but not inhibitors of secretory and Ca21-independent PLA2 or inhibitors of
PLC, rescued cells from apoptosis triggered by GFP–FAT. The panPKC inhibitor bisindolylmaleimide I blocked apoptosis triggered by
arachidonic acid, suggesting that cPLA2 is upstream of PKC l/i in this pathway. (F) Effects of blocking large and small prodomain
caspase functions on apoptosis in GFP–FAT–transfected primary RSF. RSF were cotransfected with GFP–FAT and CrmA or with
GFP–FAT alone. At 16 h, the apoptotic index of RSF transfected with GFP–FAT was high whether or not CrmA was also transfected.
The small prodomain caspase inhibitor, Z-VAD-FMK, inhibited formation of condensed and fragmented nuclei in serum-deprived
GFP–FAT–transfected fibroblasts plated on fibronectin.
lated apoptosis pathway in serum-deprived endothelial
cells and fibroblasts. (c) In anchorage-dependent fibro-
blasts, this pathway involves activation of cPLA2 and PKC
l/i, and it is Bcl2 suppressible and CrmA insensitive,
which distinguishes it from the direct death pathway trig-
gered by ligation of Fas-family death receptors. (d) The
absence of functional p53 enables serum-deprived endo-
thelial cells and fibroblasts to survive despite the absence
of FAK and/or an appropriate ECM. This is the first re-
port that survival signals from ECM, transduced by FAK
in anchorage-dependent cells, suppress p53-regulated apop-
tosis.
FAK Is Required for Transducing Survival Signals from 
ECM in Endothelial Cells and Fibroblasts
After ligation of integrins by fibronectin, FAK-containing
signaling complexes are formed at sites of adhesion (Miya-
moto et al., 1995a,b; Schlaepfer and Hunter, 1998). Previ-
ous work has correlated maintenance of survival with the
presence of activated FAK (Frisch et al., 1996; Hungerford
et al., 1996). Our studies of endothelial cells derived from
FAK1 and FAK2 EB and E8.0 embryos tested this corre-
lation directly. They documented conclusively that FAK is
required for transducing survival signals from a complex
ECM and from fibronectin. Interestingly, both FAK and
fibronectin knockout mice have similar phenotypes, show-
ing extensive mesodermal defects and embryonic death at
E8–8.5, which is consistent with the hypothesis that these
molecules have related functions (George et al., 1993; Fu-
ruta et al., 1995).
The importance of FAK in regulating survival of an-
chorage-dependent cells was confirmed by our studies
with primary fibroblasts (RSF). Endogenous FAK func-
tion was inactivated by using a dominant-negative con-
struct made of GFP fused to the FAT region of FAK. We
chose transfection of the FAT domain as the strategy for
interfering with FAK function for two reasons: first, the
FAT domain in intact FAK is responsible for targeting it
to focal contacts (Hildebrand et al., 1993), and secondly,
FAK has been shown to be cleaved by caspase activity
at an early stage of Apo-2L–mediated programmed cell
death, generating a COOH-terminal fragment similar in
size to FAT (Wen et al., 1997; Levkau et al., 1998). The ex-
pression of GFP–FAT caused a high level of apoptosis in
RSF. The importance of focal contact localization to the
proapoptotic effect of GFP–FAT was revealed by our
demonstration that expression of a FAT construct that
lacked its COOH-terminal 13 amino acids, including a
critical R1042 residue (Tachibana et al., 1995), resulted
in a significantly reduced apoptotic effect. Interestingly,
FRNK, a naturally occurring alternative product of the fak
gene, did not trigger a high level of apoptosis when trans-
fected into fibroblasts, even though, like FAT, FRNK
lacks kinase activity and can displace FAK from focal
contacts (Richardson and Parsons, 1996). Therefore, se-
quences in FRNK NH2-terminal to FAT must suppress
proapoptotic signals in the FAT domain. The ability of
these sequences in FRNK to suppress proapoptotic signals
in FAT should enable FRNK to be expressed in a regu-
lated fashion and to modulate certain functions of FAK—
for instance cell spreading (Richardson and Parsons,
1996)—without killing the cells in which it is expressed.
FAK Suppresses a p53-regulated Apoptotic Pathway
We were able to determine that p53 was involved in the
mechanism by which FAK suppresses apoptosis in anchor-
age-dependent endothelial cells as a consequence of our
immortalizing FAK1 and FAK2 endothelial cells by two
different methods: pmT infection and derivation of endo-
thelial cells from embryos that also carried a mutated
p53. Thus, pmT-transformed endothelial cells that were
FAK2 and p531 had substantially higher rates of apopto-
sis after serum withdrawal than either their FAK1p531
or FAK2p532 counterparts (Fig. 1 B).
Since transformed cells might have altered signaling
pathways, especially those that regulate survival, the in-
volvement of p53 in regulating the apoptotic pathway sup-
pressed by survival signals from ECM/FAK was addressed
more comprehensively in primary fibroblasts. In the
most direct approach, we demonstrated that a truncated
COOH-terminal portion of p53 could act in a dominant-
negative manner to interfere with the ability of GFP–FAT
to trigger apoptosis. This region of p53 contains putative
PKC phosphorylation sites, suggesting that phosphoryla-The Journal of Cell Biology, Volume 143, 1998 558
tion by PKC might function to activate or increase the
half-life of p53 (Milne et al., 1996). In contrast, mutations
in the region of p53 that is required for its DNA binding
function did not interfere with GFP–FAT–triggered apop-
tosis. These data suggest that when FAK function is sup-
pressed, p53 acts directly on downstream components of
an apoptotic cascade, rather than acting indirectly by bind-
ing DNA and trans-activating target genes. Our data indi-
cating that both E1B 19K and Bcl2 suppress apoptosis
when FAK is inactivated also support a role for p53 in this
programmed cell death pathway (Debbas and White,
1993; Ko and Prives, 1996; Levine, 1997). Thus, p53 regu-
lates an apoptotic pathway in response to loss of survival
signals from ECM and FAK in primary fibroblasts as well
as in endothelial cells.
FAK May Function in More Than One
Survival Pathway
Two important areas of investigation in this system in-
volve identifying components in the ECM survival path-
way that act downstream of FAK, and identifying factors
in the apoptotic pathway triggered by the loss of the FAK
function that act upstream and downstream of p53. Al-
though the emphasis of the work presented here has been
on characterizing the p53-regulated apoptotic pathway, we
did ascertain that PI3K and its downstream target AKT
were not involved in transmitting survival signals from
FAK in serum-deprived, anchorage-dependent fibroblasts.
This is in contrast to reports from Khwaja et al. (1997) pro-
viding evidence that PI3K/AKT lie downstream of FAK in
survival pathways, and from Xiong and Parsons (1997)
showing that constitutively activated PI3K or AKT could
rescue cells from apoptosis triggered by overexpression of
the FAK-related molecule PYK2. These latter results sug-
gested that there might be a balance in some cell types,
whereby PI3K/AKT–transmitted survival signals down-
stream of FAK keep proapoptotic signals from PYK2 in
check. The system described in the PYK2 study differed in
several respects from that presented here, suggesting that
FAK may be involved in more than one survival pathway.
First, cells in the PYK2 study were cultured in the pres-
ence of serum; therefore, they were not dependent on sur-
vival signals from ECM. Since FAK can be activated by re-
ceptors for several soluble factors, as well as by ECM
receptors, it is likely that a different pathway that involves
FAK and PI3K/AKT transmits survival signals from these
factors. Secondly, the apoptotic pathway triggered by
PYK2 overexpression was suppressible by CrmA and re-
sistant to overexpression of Bcl2, the converse of the path-
way reported here. Clearly, additional studies are required
to clarify the roles of FAK in transducing survival signals
from ECM as well as from soluble factors.
Figure 7. Model for the transmission of
matrix survival signals. Signals from fi-
bronectin are detected by fibronectin re-
ceptors and transduced by FAK. These
signals suppress a p53-dependent apop-
totic pathway in anchorage-dependent, se-
rum-deprived fibroblasts. When both
ECM and serum survival signals are ab-
sent, PKC l/i is strongly implicated in the
activation of p53, while pharmacological
evidence also supports a role for cPLA2.
FADD, Fas-associated death domain–
containing protein; LPDC, large pro-
domain caspases; SPDC, small prodomain
caspases; TRADD, TNF receptor 1–asso-
ciated death domain protein.Ili  et al. FAK, p53, and Survival 559 ´ c
The p53-regulated Apoptotic Pathway Triggered in
the Absence of FAK Function Is Activated by cPLA2 
and PKC l/i and Is Distinct from the Pathway 
Triggered by Fas-related Death Receptors
To begin to address the mechanisms by which p53 be-
comes activated when ECM-initiated survival signals are
interrupted, we started from the observation that the
COOH-terminal region of p53 containing putative PKC
phosphorylation sites could act as a dominant negative for
the function of endogenous p53, negating its ability to
propagate an apoptotic pathway. After documenting the
repertoire of PKC isoforms expressed by RSF, we used
pharmacological and dominant-negative approaches to de-
termine that PKC l/i was required for a successful apop-
totic response to the suppression of FAK function by
GFP–FAT. This result is consistent with a mechanism by
which PKC l/i phosphorylates p53 and increases its stabil-
ity and steady-state level, enabling it to propagate an apop-
totic signal. A similar pharmacological approach enabled
us to implicate cPLA2, as opposed to PLC, as a potential
activator of PKC l/i in this pathway. How cPLA2 becomes
activated inappropriately in the absence of ECM survival
signals remains to be established.
To begin to determine how p53 communicates with the
cellular death machinery once it has become activated in
response to the loss of ECM/FAK survival signals, we used
inhibitors of members of the caspase family suggested to
affect early (i.e., initiation) or later (i.e., execution) phases
of programmed cell death. CrmA, which blocks the activ-
ity of large prodomain caspases that are implicated in the
initiation phase of programmed cell death (Villa et al.,
1997), did not block p53-regulated apoptosis in RSF trig-
gered either by FAK inactivation or by culture on an inap-
propriate ECM. This suggests that the commitment to
p53-regulated apoptosis, initiated by withdrawal of ECM,
is distinct from commitment to the death pathway initiated
by Fas ligand or TNF-a (Villa et al., 1997) or by overex-
pression of the FAK family member PYK2 (Xiong and
Parsons, 1997), the apoptotic effects of which are all
blocked by CrmA. The CrmA construct we used was ac-
tive, as indicated by its ability to suppress apoptosis trig-
gered by blockade of soluble growth factor survival signals
in serum-dependent cells (data not shown).
Although programmed cell death pathways can be initi-
ated by several different mechanisms, data from many
groups suggest that these pathways merge into a final exe-
cution phase that is mediated by small prodomain caspases
(Chinnaiyan and Dixit, 1996, 1997; Villa et al., 1997). If
this is true for the p53-regulated apoptotic pathway
described here, the small prodomain caspase inhibitor,
Z-VAD-FMK, should block its terminal stages, which are
characterized by nuclear fragmentation and cell disinte-
gration. Our data support this idea: in the presence of
Z-VAD-FMK, GFP–FAT–transfected RSF were rounded,
but at 24 h there was little nuclear fragmentation or cell
body disintegration compared with controls. Thus, the
CrmA-insensitive, p53-regulated apoptotic pathway that
detects the absence of survival signals from ECM in anchor-
age-dependent RSF requires small prodomain caspases
for its execution phase.
In summary (Fig. 7), we have directly documented a role
for FAK in transducing survival signals from fibronectin in
anchorage-dependent endothelial cells and fibroblasts. By
manipulating the expression or function of FAK and/or
p53, we show that survival signals from fibronectin, trans-
duced by FAK, suppress a p53-dependent apoptotic path-
way in anchorage-dependent cells. Our data suggest that
PKC l/i and cPLA2 lie upstream of p53 in this pathway.
This pathway is suppressible by Bcl2, but not by CrmA,
distinguishing it from the direct death pathway triggered
by death ligands or PYK2 overexpression.
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